Tandem Diabetes Care (NASDAQ:TNDM) Director Christopher Twomey Sells 1,700 Shares of Company Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Christopher Twomey sold 1,700 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director owned 24,434 shares of the company’s stock, valued at $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $19.79 on Friday. Tandem Diabetes Care, Inc. has a twelve month low of $12.26 and a twelve month high of $29.65. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65. The business’s fifty day moving average is $18.09 and its 200 day moving average is $18.96.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, August 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The business had revenue of $254.56 million during the quarter, compared to analysts’ expectations of $254.99 million. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.78) EPS. Equities analysts predict that Tandem Diabetes Care, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors have recently bought and sold shares of the company. OP Asset Management Ltd bought a new position in shares of Tandem Diabetes Care in the 1st quarter worth about $35,000. Integrated Wealth Concepts LLC bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at about $33,000. Sterling Capital Management LLC boosted its position in shares of Tandem Diabetes Care by 849.0% during the 3rd quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 2,080 shares in the last quarter. Leonteq Securities AG grew its stake in Tandem Diabetes Care by 21.7% during the first quarter. Leonteq Securities AG now owns 9,501 shares of the medical device company’s stock worth $182,000 after purchasing an additional 1,695 shares during the period. Finally, Prosperitas Financial LLC acquired a new stake in Tandem Diabetes Care during the second quarter worth approximately $151,000.

Analyst Ratings Changes

TNDM has been the subject of several recent research reports. Mizuho set a $18.00 price target on shares of Tandem Diabetes Care in a research report on Tuesday, October 13th. Barclays upgraded shares of Tandem Diabetes Care to a “hold” rating in a report on Wednesday, October 7th. Citigroup reduced their price objective on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. Truist Financial reduced their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. Finally, UBS Group assumed coverage on Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $27.08.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.